Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glucocorticoids Clear all
Terminated No phase listed Observational

CT-Based Changes in Bone and Marrow Among Patients on Oral Steroids

NCT04518722
View directory record Official record
Conditions
Asthma, Bone Density, Low, Oral Steroid-Dependent Asthma (Disorder)
Interventions
CT Scan, DXA Scan, Steroid Intake Questionnaire
Radiation · Other
Lead sponsor
University of Iowa
Other
Eligibility
25 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 23, 2026, 2:52 PM EDT
Recruiting Phase 2 Interventional

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

NCT05726292
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 23, 2026, 2:52 PM EDT
Completed Phase 1 Interventional

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

NCT04373265
View directory record Official record
Conditions
Adrenocortical Carcinoma
Interventions
Relacorilant, Pembrolizumab
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Stanford, California • Tampa, Florida • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Jul 23, 2026, 2:52 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis

NCT01809132
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
Anakinra, Pentoxifylline, Zinc Sulfate, Methylprednisolone
Drug
Lead sponsor
Mack Mitchell
Other
Eligibility
21 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Louisville, Kentucky • Worcester, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 23, 2026, 2:52 PM EDT
Recruiting Phase 4 Interventional

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

NCT07221838
View directory record Official record
Conditions
Generalized Myasthenia Gravis, gMG
Interventions
Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone
Procedure · Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Chicago, Illinois • Schaumburg, Illinois • Neptune City, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 23, 2026, 2:52 PM EDT
Terminated Phase 3 Interventional Results available

The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis

NCT01349673
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide Foam
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jul 23, 2026, 2:52 PM EDT
Terminated Phase 2 Interventional Results available

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

NCT02855359
View directory record Official record
Conditions
Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
Interventions
denintuzumab mafodotin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2019 · Synced Jul 23, 2026, 2:52 PM EDT
Completed No phase listed Observational

C-myc Biomarker Study for Diabetic Foot Ulcers

NCT04591691
View directory record Official record
Conditions
Diabetes, Diabetic Foot, Diabetic Foot Ulcer, Diabetic Wound
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Jul 23, 2026, 2:52 PM EDT
Completed No phase listed Observational

Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease

NCT03817840
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Treatment of Cushing's
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jul 23, 2026, 2:52 PM EDT
Completed Not applicable Interventional Results available

Extinction of Fear Memories With Glucocorticoids in Veterans With PTSD

NCT01090180
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Dexamethasone, Placebo (sugar pill)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2016 · Synced Jul 23, 2026, 2:52 PM EDT
Recruiting Phase 2 Interventional

Dynamic Treatment Regiments for Glucocorticoid Tapering

NCT06072768
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
15-day taper prednisone, 150-day taper prednisone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Jul 23, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Midazolam Drug Interaction Study With PF-04171327

NCT00987038
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-04171327 25 mg, Midazolam 2 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 7, 2009 · Synced Jul 23, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Systemic Steroids for Peripheral Nerve Blocks

NCT02464176
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Dexamethasone, Bupivacaine, Epinephrine, Lumbar Plexus Nerve Block, Saline
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Jul 23, 2026, 2:52 PM EDT
Completed Phase 1 Interventional

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

NCT01082926
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Brain Stem Glioma, Ependymoblastoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Grade III Meningioma, Meningeal Hemangiopericytoma, Mixed Glioma, Pineal Gland Astrocytoma, Brain Tumor
Interventions
therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis, positron emission tomography
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Jul 23, 2026, 2:52 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block

NCT01538459
View directory record Official record
Conditions
Shoulder Pain, Injury of Shoulder Region, Disorder of Shoulder, Disorder of Rotator Cuff, Disorder of Tendon of Biceps
Interventions
Dexamethasone, Bupivacaine
Drug
Lead sponsor
Lifespan
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newport, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Jul 23, 2026, 2:52 PM EDT
Completed Phase 4 Interventional

Improving Bone Health Among Rheumatoid Arthritis (RA) Patients on Chronic Glucocorticoids

NCT01378689
View directory record Official record
Conditions
Adverse Effect of Glucocorticoids and Synthetic Analogues, Osteoporosis, Rheumatoid Arthritis
Interventions
Storytelling online video
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
4,659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Jul 23, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia

NCT02716818
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort®, standard glucocorticoid therapy
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Jul 23, 2026, 2:52 PM EDT
Recruiting Phase 3 Interventional

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

NCT05696613
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
SNP-ACTH (1-39) Gel, Rituximab
Drug
Lead sponsor
Cerium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Los Angeles, California • San Dimas, California • Tarzana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

NCT00051558
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate Sodium, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
6
States / cities
Loma Linda, California • Palo Alto, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Jul 23, 2026, 2:52 PM EDT
Completed Phase 1 Interventional

Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1

NCT06462781
View directory record Official record
Conditions
Refractory Migraine
Interventions
Lidocaine hydrochloride, Methylprednisolone sodium succinate
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jul 23, 2026, 2:52 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Glucocorticoid Inflammation Paradox in Human Skeletal Muscle

NCT03529929
View directory record Official record
Conditions
Aging
Interventions
Methylprednisolone
Drug
Lead sponsor
Texas A&M University
Other
Eligibility
60 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Jul 23, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Results available

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

NCT02276963
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Ublituximab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Jul 23, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

NCT00938587
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PF-04171327 10 mg, Prednisone Placebo, PF-04171327 25 mg, Prednisone 5 mg, Placebo for PF-04171327, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
10
States / cities
Anniston, Alabama • Daytona Beach, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Jul 23, 2026, 2:52 PM EDT
Terminated Phase 1Phase 2 Interventional

Prevention of Steroid-Induced Osteoporosis in Children

NCT00022841
View directory record Official record
Conditions
Osteoporosis
Interventions
Pamidronate
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
5 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 18, 2007 · Synced Jul 23, 2026, 2:52 PM EDT